Lenalidomide

證據等級: L5

預測適應症: 6 個

Lenalidomide: From Multiple Myeloma/MDS to Myeloid Leukemia

One-Sentence Summary

Lenalidomide is an oral immunomodulatory drug (IMiD) whose established use — per literature evidence in this pack — is multiple myeloma and del(5q)-associated myelodysplastic syndrome (MDS). The TxGNN model predicts it may be effective for Myeloid Leukemia, with 50 clinical trials and 20 publications currently identified, though only a subset are graded as directly relevant.

Quick Overview

Item	Content
Original Indication	Not available from `taiwan_regulatory.licenses` (no records — drug not marketed in New Zealand). Literature evidence (PMID 23316859) notes Lenalidomide is approved for transfusion-dependent anemia in del(5q) MDS and for multiple myeloma in combination with dexamethasone.
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.49%
Evidence Level	L2
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (original_moa: [Data Gap]). Based on the literature evidence included in the pack (PMID 23316859), Lenalidomide is an oral immunomodulatory drug derived from thalidomide, with established efficacy in transfusion-dependent anemia due to del(5q) myelodysplastic syndrome and in multiple myeloma (combined with dexamethasone). Its mechanism is understood to act through cereblon (CRBN)-mediated degradation of IKZF1/IKZF3, driving immunomodulatory and anti-angiogenic effects (supported by PMID 39881283, which describes CRBN stabilization as central to Lenalidomide's antileukemic activity).

Myelodysplastic syndrome and acute/myeloid leukemia exist on a biological continuum: MDS is a clonal hematopoietic stem-cell disorder that carries a well-documented risk of transformation into myeloid leukemia. Because Lenalidomide's efficacy is already established at the MDS end of this spectrum, extending its immunomodulatory and anti-angiogenic mechanism to myeloid leukemia — particularly in combination with hypomethylating agents such as azacitidine — has clear biological plausibility. This is consistent with the evidence pack's own rationale: "AML/MDS are both malignant proliferative disorders of hematopoietic stem cells; Lenalidomide's immunomodulatory and anti-angiogenic mechanism has clear benefit on the MDS side and extending to AML (especially combined with azacitidine) is biologically plausible, but AML-specific evidence independent of MDS remains at Phase 1/2."

However, evidence specific to myeloid leukemia (as opposed to MDS broadly) remains concentrated in Phase 1/2 trials, with only one Phase 3 AML-maintenance trial (NCT04490707, status UNKNOWN) identified, supporting the L2 evidence-level classification rather than a higher tier.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01904643	Phase 1	Terminated	17	Lenalidomide prior to MEC re-induction chemotherapy in relapsed/refractory AML — direct AML population (Grade A).
NCT01246622	Phase 1	Completed	32	Cytarabine + Lenalidomide in relapsed/refractory AML — direct AML population (Grade A).
NCT00839059	Phase 1	Terminated	14	Dose-escalation of Lenalidomide monotherapy in newly diagnosed/relapsed/refractory AML (Grade A).
NCT00744536	Phase 2	Completed	20	Lenalidomide + metronomic melphalan in higher-risk MDS/CMML, anti-angiogenic rationale (Grade B).
NCT04490707	Phase 3	Unknown	60	Azacitidine + Lenalidomide as MRD-guided maintenance in elderly/unfit AML.
NCT01016600	Phase 1/2	Completed	31	Azacitidine + Lenalidomide for AML — toxicity and remission rates.
NCT02126553	Phase 2	Completed	29	Lenalidomide maintenance in high-risk AML in remission.
NCT02472691	Phase 2	Completed	50	Lenalidomide + azacitidine + DLI for MDS/CMML/AML relapse after allogeneic transplant.
NCT00352365	Phase 2	Completed	41	Lenalidomide monotherapy in previously untreated del(5q) AML, patients ≥60 declining induction chemo.
NCT00360672	Phase 2	Completed	27	Lenalidomide in relapsed/refractory AML or high-risk MDS with chromosome 5 abnormalities.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34955443	2022	Phase 1b trial	Journal of Geriatric Oncology	Lenalidomide as post-remission therapy in older AML adults — safety and geriatric functional assessment.
31221030	2019	Systematic Review/Meta-analysis	Hematology (Amsterdam)	Azacitidine + Lenalidomide efficacy/adverse events across AML, MDS, and CMML.
23644421	2013	Cohort	Leukemia	Review of azacitidine + lenalidomide combination in MDS/AML — rationale and outcomes.
37259567	2023	Cohort (Azalena Trial)	Haematologica	Azacitidine + Lenalidomide + DLI for post-transplant relapse of AML/MDS/CMML.
37435080	2023	Cohort	Frontiers in Immunology	Azacitidine + low-dose Lenalidomide as relapse-prophylaxis after allo-HSCT in AML.
23316859	2013	Review	Expert Opinion on Investigational Drugs	Overview of Lenalidomide as a novel AML treatment; source for original MDS/myeloma indication context.
30653424	2019	Trial	Journal of Clinical Oncology	Lenalidomide + azacitidine as salvage therapy after allo-SCT relapse in AML.
40250191	2025	Phase 1 trial	Leukemia Research	Lenalidomide + bortezomib in AML/MDS relapsing after allogeneic stem cell transplant.
34471239	2021	pending	Bone Marrow Transplantation	Safety/tolerability of Lenalidomide maintenance in post-transplant AML and high-risk MDS.
37288607	2023	Review	American Journal of Hematology	2023 update on MDS diagnosis, risk-stratification, and management, including progression to AML.

New Zealand Market Information

Currently not marketed in New Zealand — no authorization records found (total_licenses: 0, licenses: []).

Cytotoxicity

Lenalidomide is classified here as an antineoplastic agent (hematologic malignancy indications per literature evidence: multiple myeloma, MDS, and the predicted myeloid leukemia indication).

Item	Content
Cytotoxicity Classification	Targeted therapy — immunomodulatory imide drug (IMiD); non-classical cytotoxic, cereblon (CRBN)-mediated mechanism
Myelosuppression Risk	Please refer to the package insert warnings and precautions (neutropenia and thrombocytopenia are frequently reported adverse events across the cited combination trials, but no quantified toxicity data is available in this evidence pack)
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. (key_warnings, contraindications, and DDI query all returned no data in this evidence pack — DDI query status: not_found.)

Conclusion and Next Steps

Decision: Hold

Rationale:

A Blocking-severity data gap (DG001: TFDA/Medsafe package insert — warnings and contraindications) prevents entry into S1 safety evaluation, and the drug is not currently marketed in New Zealand (0 authorizations). While the myeloid leukemia signal is biologically plausible and supported by L2-level evidence (multiple completed Phase 1/2 trials, one Phase 3 AML-maintenance trial of unknown status), safety data is entirely absent, so the candidate cannot advance past the research-question stage.

To proceed, the following is needed:

TFDA/Medsafe package insert (warnings, contraindications) — resolves the blocking gap (DG001)
Confirmed original approved indication and mechanism of action (DrugBank API query) — resolves DG002
Drug-drug interaction (DDI) data, currently not_found
Follow-up on NCT04490707 (Phase 3, AML maintenance) completion status, currently UNKNOWN
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.